Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences appoints SVP for liver disease unit

Gilead Sciences appoints SVP for liver disease unit

10th June 2010

Gilead Sciences has chosen Dr John McHutchison as the new senior vice-president (SVP) of its liver disease therapeutics division.

Dr McHutchison, the former associate director of the Duke Clinical Research Institute at the Duke University Medical Center, is a recognised authority in the fields of gastroenterology and hepatology.

In his new role, he will take responsibility for overseeing the firm’s research and development efforts in the fields of liver disease, including hepatitis B and C.

Dr McHutchison expressed confidence about the firm’s ability to create new treatments in areas where there remains an unmet medical need.

He added: “The strength of Gilead’s scientific leadership and the unique opportunity to help shape future therapeutic possibilities for many patients with liver disease led to my keen interest in the company.”

Last month, Gilead Sciences initiated a new share repurchase programme after expressing confidence in its growth prospects in the coming years.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.